Overview

XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke

Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Recurrent stroke and cognitive decline are common after ischaemic stroke. Allopurinol, a drug usually used to treat gout, has been shown to reduce heart ischaemia, heart size, and arterial stiffness and to relax brain blood vessels and may reduce the blood pressure. All of these properties may be associated with a lower risk of second stroke and cognitive decline. We now aim to explore whether allopurinol will reduce further damage to the brain (called white matter hyper-intensities) after stroke and also whether it reduces heart size and blood pressure after stroke. We will conduct a multi-centre randomised, double-blind placebo controlled study to investigate whether two years allopurinol 300 mg twice per day (BD) improves these 3 outcomes, which are inextricably linked to risk of recurrence and cognitive decline after ischaemic stroke.
Phase:
Phase 4
Details
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborator:
University of Glasgow
Treatments:
Allopurinol